
Innate Pharma S.A. – NASDAQ:IPHA
Innate Pharma S.A. stock price today
Innate Pharma S.A. stock price monthly change
Innate Pharma S.A. stock price quarterly change
Innate Pharma S.A. stock price yearly change
Innate Pharma S.A. key metrics
Market Cap | 166.54M |
Enterprise value | 162.76M |
P/E | -36.56 |
EV/Sales | 8.85 |
EV/EBITDA | -85.93 |
Price/Sales | 10.28 |
Price/Book | 1.75 |
PEG ratio | N/A |
EPS | -0.13 |
Revenue | 82.72M |
EBITDA | -21.10M |
Income | -11.35M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -28.12% |
Oper. margin | -22.72% |
Gross margin | 14.28% |
EBIT margin | -22.72% |
EBITDA margin | -25.51% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInnate Pharma S.A. stock price history
Innate Pharma S.A. stock forecast
Innate Pharma S.A. financial statements
Mar 2023 | 20.09M | 859K | 4.27% |
---|---|---|---|
Jun 2023 | 35.34M | 1.71M | 4.86% |
Sep 2023 | 10.72M | -4.64M | -43.31% |
Dec 2023 | 16.55M | -9.28M | -56.1% |
2025 | 96.85M | 20.85M | 21.53% |
---|---|---|---|
2026 | 123.51M | 22.80M | 18.47% |
2027 | 68.07M | -19.89M | -29.23% |
2028 | 138.18M | 28.64M | 20.73% |
Analysts Price target
Financials & Ratios estimates
Apr 2023 | 199049000 | 141.18M | 70.93% |
---|---|---|---|
Jun 2023 | 199049000 | 141.18M | 70.93% |
Sep 2023 | 184193000 | 132.29M | 71.82% |
Dec 2023 | 184193000 | 132.29M | 71.82% |
Mar 2023 | -5.73M | -123K | -623K |
---|---|---|---|
Jun 2023 | -11.46M | -246K | -1.24M |
Sep 2023 | -10.54M | 10.43M | -360K |
Dec 2023 | -21.09M | 20.87M | -720K |
Innate Pharma S.A. alternative data
Aug 2023 | 211 |
---|---|
Sep 2023 | 211 |
Oct 2023 | 191 |
Nov 2023 | 191 |
Dec 2023 | 191 |
Jan 2024 | 191 |
Feb 2024 | 191 |
Mar 2024 | 191 |
Apr 2024 | 191 |
May 2024 | 179 |
Jun 2024 | 179 |
Jul 2024 | 179 |
Innate Pharma S.A. other data
Quarter | Transcript |
---|---|
Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 21 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 14 Sep 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Mondher Mahjoubi M.D. (1958) Chairman of Executive Board & Chief Executive Officer | $747,830 |
Mr. Yannis Morel (1973) Executive Vice President of Product Portfolio Strategy & Bus. Devel. and Member of Executive Board | $345,050 |
Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA (1978) Executive Vice President of Fin. & Corporation Strategy | $288,940 |
-
What's the price of Innate Pharma S.A. stock today?
One share of Innate Pharma S.A. stock can currently be purchased for approximately $2.29.
-
When is Innate Pharma S.A.'s next earnings date?
Unfortunately, Innate Pharma S.A.'s (IPHA) next earnings date is currently unknown.
-
Does Innate Pharma S.A. pay dividends?
No, Innate Pharma S.A. does not pay dividends.
-
How much money does Innate Pharma S.A. make?
Innate Pharma S.A. has a market capitalization of 166.54M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.56% to 51.9M US dollars.
-
What is Innate Pharma S.A.'s stock symbol?
Innate Pharma S.A. is traded on the NASDAQ under the ticker symbol "IPHA".
-
What is Innate Pharma S.A.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Innate Pharma S.A.?
Shares of Innate Pharma S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Innate Pharma S.A.'s key executives?
Innate Pharma S.A.'s management team includes the following people:
- Dr. Mondher Mahjoubi M.D. Chairman of Executive Board & Chief Executive Officer(age: 67, pay: $747,830)
- Mr. Yannis Morel Executive Vice President of Product Portfolio Strategy & Bus. Devel. and Member of Executive Board(age: 52, pay: $345,050)
- Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA Executive Vice President of Fin. & Corporation Strategy(age: 47, pay: $288,940)
-
How many employees does Innate Pharma S.A. have?
As Jul 2024, Innate Pharma S.A. employs 179 workers, which is 6% less then previous quarter.
-
When Innate Pharma S.A. went public?
Innate Pharma S.A. is publicly traded company for more then 5 years since IPO on 17 Oct 2019.
-
What is Innate Pharma S.A.'s official website?
The official website for Innate Pharma S.A. is innate-pharma.com.
-
How can i contact Innate Pharma S.A.?
Innate Pharma S.A. can be reached via phone at +33 4 30 30 30 30.
Innate Pharma S.A. company profile:

Innate Pharma S.A.
innate-pharma.comNASDAQ
168
Biotechnology
Healthcare
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Marseille, 13009
CIK: 0001598599
ISIN: US45781K2042
CUSIP: 45781K204